Top Markets
#1 TENDIES TENDIES +31.93%
#2 Cash Cat Cash Cat +17.71%
#3 OSK OSK +15.33%
#4 Seeker Seeker +8.17%
#5 Tornado Cash Tornado Cash +6.73%
#6 Big Time Big Time +6.31%
#7 Nesa Nesa +6.00%
#8 UnifAI Network UnifAI Network +5.06%
#9 Staked ZIG Staked ZIG +4.30%
#10 Jelly-My-Jelly Jelly-My-Jelly +4.11%
Coin of the day
TENDIES TENDIES
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Classifica tra le azioni #16417
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Prezzo delle azioni
$3.12
Ultima sincronizzazione: 2026-09-01
Capitalizzazione di mercato
$294.21M
Variazione (1 giorno)
-3.26%
Variazione (1 anno)
-54.86%
Paese
US
Scambia Myriad Genetics, Inc. (MYGN)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per Myriad Genetics, Inc. (MYGN)
L’azione Myriad Genetics, Inc. (simbolo: MYGN) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Sep 02, 2026.
Una quota di MYGN acquistata prima di Sep 02, 2026 equivale oggi a 0 quote di MYGN.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 8 x34
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 7 x47
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 0 -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 0 -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 4 x15
US